Sam H. Jiang1, David M. Benedek2, Patricia Spangler2, James West2, Catherine L. Dempsey2, Ashley Phares2, Brian Andrews-Shigaki3, Eduardo Coello1, and Alexander P. Lin1
1Center for Clinical Spectroscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States, 2Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 3Office of Naval Research, United States Navy and Marine Corps, Alexandria, VA, United States
1Center for Clinical Spectroscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States, 2Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 3Office of Naval Research, United States Navy and Marine Corps, Alexandria, VA, United States
The addition of riluzole to ongoing selective serotonin reuptake inhibitor therapy for combat-related post-traumatic stress disorder modulated glutamate-glutamine cycling, improved neural energetics, and induced cholinergic changes indicative of neuroprotective inflammation.
Figure 3. Distributions of anterior cingulate cortex (ACC) a) phosphocholine + glycerophosphocholine (tCho) in the overall, riluzole, and placebo cohorts, and b) creatine + phosphocreatine (tCr) in the riluzole and placebo cohorts (* = p < 0.05, ** = p < 0.01).
Figure 4. Distributions of amygdala a) glutamine (Gln) in the overall and placebo cohorts, and b) glutamate + glutamine (Glx) in the riluzole cohort (* = p < 0.05).
